GlassScriptPhysician profile
Cheri L Fogle
NPI 1518959923
$1,486.43
in general payments reported to CMS, 2019-2025
21 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $112 · 2023: $398 · 2024: $241 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.07 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $265.60 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $193.17 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $186.10 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.57 | 2021-2025 | |
| Pfizer INC. | $102.32 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $80.60 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $80.21 | 2021-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $65.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $56.72 | 2023-2025 | Farxiga |
| Phathom Pharmaceuticals, INC. | $55.89 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $55.39 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $51.36 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.81 | 2022-2025 | Jardiance |
| Axsome Therapeutics, INC. | $30.37 | 2025 | Auvelity |
| Ardelyx, INC. | $22.34 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.01 | 2022 | |
| Abbott Laboratories | $19.17 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $17.90 | 2025 | Abilify Maintena |
| Corcept Therapeutics | $15.08 | 2024 | Korlym |
| Corium, LLC | $12.07 | 2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheri Fogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.